The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...

The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Professor Hirohide Saito and his research team have developed a new microRNA-responsive hybrid mRNA switch, enabling precise, ...

These trends, along with intensified global efforts in product development, are driving innovation, expanding manufacturing capacity, and strengthening the global mRNA synthesis and production market.

Nutcracker Therapeutics and Elegen see their mission as delivering scalable and low-cost RNA manufacturing for individualized therapies.

Researchers from Tel Aviv University and the Israel Institute for Biological Research in Ness Ziona have used the platform ...

Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden ...

Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.

Smart mRNA drugs listen to the body, adjusting protein production based on disease-related signals by University of Osaka ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...